Browse medicines, page 4 of 10
Some records contain detailed evidence; others currently contain only basic identity and regulatory information. Reviewed conclusions appear only when they are available for a specific use and group of people.
Showing 181–240 of 546 records
Cocarboxylase (Enbrace Hr / Paxlyte)
Protein medicineUsed in a way not covered by an approval, or made by a compounding pharmacyExpanded recordUse listed on the medicine record
INDICATIONS: EnBrace HR ® is indicated in the TREATMENT of vitamin deficiency - specifically vitamin B 12 deficiency, and the PREVENTION of vitamin B 12 -cofactor deficiency, l-methylfolate. Requirements of vitamin B 9 and/or vitamin B 12 in excess of normal due to pregnancy can usually be met with oral supplementation.
Datopotamab Deruxtecan (Datroway)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
DATROWAY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of: adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. ( 1.1 ) This indication is approved under accelerated approval based on objective response rate and duration of response [see Clinical Studies (14.1) ] .
Decarboxylase
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordDenosumab-Mobz (Boncresa / Oziltus)
Protein medicineApproved in the United States (FDA)Expanded recordDonanemab-Azbt (Kisunla)
Protein medicineApproved in the United States (FDA)Expanded recordDostarlimab-Gxly (Jemperli)
Protein medicineApproved in the United States (FDA)Expanded recordEfbemalenograstim alfa (Ryzneuta)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
RYZNEUTA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Limitations of Use RYZNEUTA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.
Eflapegrastim-Xnst (Rolvedon)
Protein medicineApproved in the United States (FDA)Expanded recordElapegademase (Revcovi)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
Adenosine deaminase severe combined immune deficiency
Enfortumab Vedotin (Padcev Ejfv)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
Muscle invasive bladder cancer
Epoetin Alfa-Epbx (Retacrit)
Protein medicineApproved in the United States (FDA)Expanded recordFibrinolysin (Elase-Chloromycetin)
Protein medicineApproved in the United States (FDA)Expanded recordField Mushroom (Mushroom)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
BOTANICAL PURITY FOR A YOUTHFUL COMPLEXION SOOTHES, PROTECTS, AND BALANCES SENSITIVE SKIN It relieves dry, flaky skin and protects against irritation and harmful microbes, restoring balance to your skin.
Hemicellulase
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordHemin (Panhematin)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
The amelioration of recurrent attacks of acute intermittent porphyria temporally related to the menstrual cycle in susceptible women, after
Hepatitis B Virus Subtype Adw Hbsag Surface Protein Antigen (Recombivax Hb / Heplisav-B)
Protein medicineLaboratory or animal-stage researchExpanded recordHuman Papillomavirus Type 31 L1 Capsid Protein Antigen (Gardasil 9)
Protein medicineLaboratory or animal-stage researchExpanded recordHuman Rotavirus A Type G3p7 Strain Wi78 Live Antigen (Rotateq)
Protein medicineLaboratory or animal-stage researchExpanded recordHuman Thrombin (Thrombin Human)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
Use with manual compression
Ibalizumab-Uiyk (Trogarzo)
Protein medicineApproved in the United States (FDA)Expanded recordIdursulfase (Elaprase)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Hunter syndrome
Imiglucerase (Cerezyme)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Non-central nervous system (CNS) manifestations of Type 1 or Type 3 Gaucher disease
Infliximab-Abda (Renflexis)
Protein medicineApproved in the United States (FDA)Expanded recordInfliximab-Axxq (Avsola)
Protein medicineApproved in the United States (FDA)Expanded recordInfluenza A Virus A/Switzerland/6849/2025 Ivr-278 Antigen (Fluzone Tiv Sh 2026 / Fluzone Trivalent Northern Hemisphere / Fluzone / Fluzone High Dose Northern Hemisphere)
Protein medicineLaboratory or animal-stage researchExpanded recordInsulin Aspart Recombinant (Novolog / Novolog Penfill / Novolog Innolet)
Protein medicineApproved in the United States (FDA)Expanded recordInsulin Aspart-Xjhz (Kirsty)
Protein medicineApproved in the United States (FDA)Expanded recordInsulin Detemir Recombinant (Levemir / Levemir Innolet / Levemir Penfill)
Protein medicineApproved in the United States (FDA)Expanded recordLactoperoxidase
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordLanadelumab-Flyo (Takhzyro)
Protein medicineApproved in the United States (FDA)Expanded recordLonapegsomatropin (Skytrofa)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
SKYTROFA (lonapegsomatropin-tcgd) is a human growth hormone indicated for the: Treatment of pediatric patients 1 year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone (GH). Replacement of endogenous growth hormone in adults with growth hormone deficiency (GHD). SKYTROFA is a human growth hormone indicated for: Pediatric Patients: Treatment of pediatric patients 1 year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone (GH) ( 1 ).
Luspatercept-Aamt (Reblozyl)
Protein medicineApproved in the United States (FDA)Expanded recordMalt Diastase
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordMeasles Virus Strain Enders' Attenuated Edmonston Live Antigen (M-M-R II / Proquad)
Protein medicineLaboratory or animal-stage researchExpanded recordMucor Circinelloides F. Lusitanicus
Protein medicineLaboratory or animal-stage researchExpanded recordNeisseria Meningitidis Group Y Capsular Polysaccharide Tetanus Toxoid Conjugate Antigen (Menquadfi)
Protein medicineLaboratory or animal-stage researchExpanded recordPeptidase
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordSomapacitan (Sogroya)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
Pediatric patients aged 2
Streptococcus Pneumoniae Type 33f Capsular Polysaccharide Diphtheria Crm197 Protein Conjugate Antigen (Vaxneuvance / Capvaxive / Prevnar 20)
Protein medicineLaboratory or animal-stage researchExpanded recordStreptococcus Pneumoniae Type 9v Capsular Polysaccharide Diphtheria Crm197 Protein Conjugate Antigen (Vaxneuvance / Prevnar 13 / Prevnar 20)
Protein medicineLaboratory or animal-stage researchExpanded recordAlglucosidase alfa (Lumizyme / Myozyme)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Pompe disease
Amivantamab and Hyaluronidase-Lpuj (Rybrevant Faspro)
Protein medicineApproved in the United States (FDA)Expanded recordAnsuvimab-Zykl (Ebanga)
Protein medicineApproved in the United States (FDA)Expanded recordAprotinin (Trasylol)
Protein medicineApproved in the United States (FDA)Expanded recordAsparaginase (Elspar / Rylaze)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma
Atacicept-Vymj (Trutakna)
Protein medicineApproved in the United States (FDA)Expanded recordAtezolizumab and Hyaluronidase-Tqjs (Tecentriq Hybreza)
Protein medicineApproved in the United States (FDA)Expanded recordAutologous Cultured Chondrocytes (Maci)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
The repair of single or multiple symptomatic, full-thickness cartilage defects of the knee with or without bone involvement
Avalglucosidase Alfa-Ngpt (Nexviazyme)
Protein medicineApproved in the United States (FDA)Expanded recordAxatilimab-Csfr (Niktimvo)
Protein medicineApproved in the United States (FDA)Expanded recordBacillus Anthracis Strain V770-Np1-R Antigens (Cyfendus / Biothrax)
Protein medicineLaboratory or animal-stage researchExpanded recordBacillus Calmette-Guerin Substrain Tice Live Antigen (BCG Vaccine / Tice BCG)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
TICE ® BCG is indicated for: the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR) Limitations of Use: TICE BCG is not recommended for stage TaG1 papillary tumors, unless they are judged to be at high risk of tumor recurrence. TICE BCG is not indicated for papillary tumors of stages higher than T1.
Becaplermin (Regranex / Regranex Gel 0.01%)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply, when used
Belantamab Mafodotin (Blenrep)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
Relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome
Berahyaluronidase Alfa-Pmph (Keytruda)
Protein medicineApproved in the United States (FDA)Expanded recordBevacizumab-Bvzr (Zirabev)
Protein medicineApproved in the United States (FDA)Expanded recordBevacizumab-Maly (Alymsys)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Alymsys is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. (1.1) Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. (1.1) Limitations of Use: Alymsys is not indicated for adjuvant treatment of colon cancer.
Binetrakin (Guna-Il 4)
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordUse listed on the medicine record
DIRECTIONS Take 15 minutes before meals. Adults and children 12 years and older 20 drops twice a day in a little water. Hold in the mouth for about 30 seconds then swallow. Children between 12 years and 6 years of age 10 drops twice a day in a little water. Hold in the mouth for about 30 seconds then swallow. Children under 6 years consult a physician
Brentuximab Vedotin (Adcetris)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
ADCETRIS is a CD30-directed antibody and microtubule inhibitor conjugate indicated for treatment of: • Adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine ( 1.1 ). • Pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide ( 1.2 ).
Calfactant (Infasurf Preservative Free / Infasurf)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
The risk of respiratory distress syndrome (RDS) in preterm neonates <29 weeks of gestational age at risk for RDS